Osaic Holdings’s Avalo Therapeutics AVTX Stock Holding History

Osaic Holdings’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18	Hold	1	–	–	﹤0.01%	7928
2026 Q1	$14	Hold	1	–	–	﹤0.01%	7730
2025 Q4	$18	Sell	1 -1	-50%	-$17	﹤0.01%	7743
2025 Q3	$18	Hold	2	–	–	﹤0.01%	7834
2025 Q2	$8	Hold	2	–	–	﹤0.01%	7697
2025 Q1	$16	Hold	2	–	–	﹤0.01%	7357
2024 Q4	$14	Hold	2	–	–	﹤0.01%	7338
2024 Q3	$19	Hold	2	–	–	﹤0.01%	7340
2024 Q2	$24	Hold	2	–	–	﹤0.01%	7333
2024 Q1	$43	Buy	2 +1	+100%	+$5	﹤0.01%	7087
2023 Q4	$9	Hold	1	–	–	﹤0.01%	7238
2023 Q3	$42	Hold	1	–	–	﹤0.01%	7283
2023 Q2	$118	Hold	1	–	–	﹤0.01%	7265
2023 Q1	$584	Buy	+1	New	+$788	﹤0.01%	7095
2022 Q4	–	Hold	0	–	–	–	7168
2022 Q3	–	Hold	0	–	–	–	7245
2022 Q2	–	Hold	0	–	–	–	7326
2022 Q1	–	Hold	0	–	–	–	7229
2021 Q4	–	Hold	0	–	–	–	7131
2021 Q3	–	Hold	0	–	–	–	6972
2021 Q2	–	Hold	0	–	–	–	6675
2021 Q1	–	Hold	0	–	-$1K	–	6791
2020 Q4	–	Hold	0	–	–	–	6171
2020 Q3	–	Hold	0	–	–	–	6196
2020 Q2	–	Hold	0	–	–	–	5895
2020 Q1	–	Hold	0	–	–	–	5795

Other funds holding AVTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Osaic Holdings's AVTX Position: Q2 2026 in Review

Osaic Holdings held its Avalo Therapeutics (AVTX) position steady in Q2 2026 at 1 share worth $18. The position accounts for ﹤0.01% of the portfolio, ranked #7928.

Osaic Holdings first reported a position in AVTX in Q1 2023 and has held it in 14 quarters since. The position peaked at $584 in Q1 2023. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

Osaic Holdings held 1 share of Avalo Therapeutics worth $18 as of Q2 2026.
Osaic Holdings left its Avalo Therapeutics share count unchanged in Q2 2026.
Avalo Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #7928 holding.
Osaic Holdings first reported a position in Avalo Therapeutics in Q1 2023 and has held it in 14 quarters since.
Osaic Holdings's Avalo Therapeutics position peaked at $584 in Q1 2023.
126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.